In addition, in an NSCLC patient‐derived xenograft with KRAS G12C mutation, ARS‐1620 showed tumor regression, and effectively inhibited the downstream ERK phosphorylation and activated apoptosis.95 Here, KRAS is linked to non-small cell lung carcinoma.